Forsta AP Fonden Purchases 13,200 Shares of PerkinElmer, Inc. (NYSE:PKI)

Forsta AP Fonden raised its position in PerkinElmer, Inc. (NYSE:PKI) by 37.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,000 shares of the medical research company’s stock after purchasing an additional 13,200 shares during the quarter. Forsta AP Fonden’s holdings in PerkinElmer were worth $8,318,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PKI. Alliancebernstein L.P. raised its position in shares of PerkinElmer by 150.2% during the third quarter. Alliancebernstein L.P. now owns 447,187 shares of the medical research company’s stock worth $77,493,000 after acquiring an additional 268,427 shares during the last quarter. NN Investment Partners Holdings N.V. raised its position in shares of PerkinElmer by 60.1% during the third quarter. NN Investment Partners Holdings N.V. now owns 91,454 shares of the medical research company’s stock worth $15,849,000 after acquiring an additional 34,337 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its position in shares of PerkinElmer by 143.5% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 80,006 shares of the medical research company’s stock worth $13,864,000 after acquiring an additional 47,150 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in PerkinElmer by 7.2% in the third quarter. Teacher Retirement System of Texas now owns 48,119 shares of the medical research company’s stock worth $8,339,000 after purchasing an additional 3,239 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in PerkinElmer by 6.6% in the third quarter. Lord Abbett & CO. LLC now owns 267,052 shares of the medical research company’s stock worth $46,278,000 after purchasing an additional 16,462 shares in the last quarter. Hedge funds and other institutional investors own 80.93% of the company’s stock.

NYSE:PKI opened at $178.47 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.40 and a current ratio of 1.97. PerkinElmer, Inc. has a 52-week low of $119.95 and a 52-week high of $203.16. The firm has a market cap of $22.52 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 0.62 and a beta of 1.08. The business’s fifty day moving average is $185.47 and its 200 day moving average is $178.45.

PerkinElmer (NYSE:PKI) last posted its earnings results on Tuesday, November 2nd. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.70 by $0.61. PerkinElmer had a return on equity of 30.57% and a net margin of 22.41%. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the business earned $2.09 earnings per share. Equities analysts predict that PerkinElmer, Inc. will post 10.97 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 11th. Shareholders of record on Friday, January 21st will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.16%. The ex-dividend date of this dividend is Thursday, January 20th. PerkinElmer’s payout ratio is 2.79%.

A number of equities research analysts have weighed in on the company. Wells Fargo & Company lifted their target price on PerkinElmer from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Tuesday, December 14th. Robert W. Baird raised their price objective on PerkinElmer from $183.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, November 3rd. They noted that the move was a valuation call. The Goldman Sachs Group assumed coverage on PerkinElmer in a research note on Thursday, December 16th. They issued a “neutral” rating and a $200.00 price objective for the company. Finally, Royal Bank of Canada raised their price objective on PerkinElmer from $49.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 17th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $164.48.

In other PerkinElmer news, insider Daniel R. Tereau sold 3,546 shares of the company’s stock in a transaction that occurred on Thursday, December 9th. The stock was sold at an average price of $189.55, for a total transaction of $672,144.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

About PerkinElmer

PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments.

Featured Story: S&P 500 Index

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.